Delhi, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Global Bicycle Toxin Conjugates Clinical Trials & Market Opportunity Insight 2024 Report Highlights:
- Clinical Research & Market Trends by Indication
- Bicycle Toxin Conjugates Proprietary Platforms
- Current & Future Market Trends Outlook
- Clinical Research & Market Trends by Region: US, UK & EU
- Comprehensive Insight On All Drugs In Clinical Pipeline By Company, Indication & Phase
Download Report
Bicycle toxin conjugates (BTCs) are a novel class of targeted cancer therapeutics with the potential to shift therapy paradigms and enhance patient outcomes. Bicycle toxin conjugates are made up of three components: a bicyclic peptide that binds to cancer cells, a toxin payload that kills cancer cells once internalized, and a linker that connects the two.
The bicyclic peptide serves as the targeting component of BTCs. A bicyclic peptide is made up of two looped peptide chains that are linked together to form a stable 3D structure. This enables for high affinity binding to molecular targets on cancer cells. Bicycle Therapeutics used their proprietary bicyclic peptide screening method to uncover peptides with high selectivity for cancer versus normal tissue. Once the BTC binds to its target on cancer cells, the linker connecting the toxin payload is cleaved by protease action within the cells. This releases the payload that causes cancer cells to die. Linker optimization contributes to steady circulation with regulated toxin release only after cancer cell internalization.
Payloads conjugated to BTCs include highly potent toxins such as auristatins, maytansine, and their derivatives, which kill cells by disrupting microtubule activity. Due of their extreme cytoxicity, just pico molecular doses are required on each BTC. The bicyclic peptide and linker deliver the poison to targeted tumor locations. This novel three-component design allows BTCs to selectively target cancer cells while preserving healthy cells. In preclinical trials, BTCs demonstrated three to tenfold more potency than antibody-drug conjugates. Compared to antibodies, their small size allows for improved tumor penetration.
Bicycle Therapeutics led the development of BTCs by leveraging its expertise in bicyclic peptide screening. It has more than 5 BTC clinical and preclinical initiatives addressing solid and hematological malignancies. The lead candidate, BT1718, is being examined in phase 1/2 trials and has shown early indicators of anticancer efficacy.
BTCs are well positioned to gain market share from other biologics such as antibody-drug conjugates. Their innovative bicyclic peptide delivery technology allows for the targeting of novel antigens. Streamlined creation of bicyclic peptides may allow for speedier optimization. Given their medicinal benefits, BTCs are well positioned to capture a sizable market share. Overall, BTCs have the potential to improve the therapeutic index when compared to existing targeted biologics.
Bicycle Therapeutics intends to bring next generation BTCs to the clinic soon, establishing a strong pipeline of molecularly targeted cancer treatments. As more BTC candidates go through clinical trials, their use as targeted therapeutics may extend beyond cancer to other disease areas. BTCs have the potential to become essential components of modern cancer therapy regimens, revolutionizing clinical practice.
